Table 10:
Adverse Outcomes After TAVI or SAVR in Low-Risk Patients: As-Treated Analysis
| Author, Year | All-Cause Mortality, N (%) | Cardiovascular Mortality, N (%) | Paravalvular Aortic Regurgitation, N (%) | Stroke, N (%) | Major Vascular Complications, N (%) | Major Bleeding, N (%) | Permanent Pacemaker, N (%) | Myocardial Infarction, N (%) | Renal Failure, N (%) |
|---|---|---|---|---|---|---|---|---|---|
| NOTION Trial (TF TAVI) | |||||||||
|
30 days Thyregod et al, 201522 |
TAVI: 3 (2.1) SAVR: 5 (3.7) P = .43 |
TAVI: 3 (2.1) SAVR: 5 (3.7) P = .43 |
NA | TAVI: 2 (1.4) SAVR: 4 (3.0) P = .37 |
TAVI: 8 (5.6) SAVR: 2 (1.5) P = .10 |
TAVI: 16 (11.3) SAVR: 28 (20.9) P = .03 |
TAVI: 46 (34.1) SAVR: 2 (1.6) P < .001 |
TAVI: 4 (2.8) SAVR: 8 (6.0) P = .20 |
TAVI: 1 (0.7) SAVR: 9 (6.7) P = .01 |
|
1 year Thyregod et al, 201522 |
TAVI: 7 (4.9) SAVR: 10 (7.5) P = .38 |
TAVI: 6 (4.3) SAVR: 10 (7.5) P = .25 |
NA | TAVI: 4 (2.9) SAVR: 6 (4.6) P = .44 |
NA | NA | TAVI: 51 (38) SAVR: 3 (2.4) P < .001 |
TAVI: 5 (3.5) SAVR: 8 (6.0) P = .33 |
NA |
| STACCATO Trial (TA TAVI) | |||||||||
|
30 days Nielsen et al, 201223 |
TAVI: 1 (2.9) SAVR: 0 (0) |
TAVI: 1 (2.9) SAVR: 0 (0) |
NA | TAVI: 2 (5.9) SAVR: 1 (2.8) |
TAVI: 1 (2.9) SAVR: 0 (0) |
TAVI: 1 (2.9) SAVR: 1 (2.8) |
TAVI: 2 (5.9) SAVR: 1 (2.8) |
TAVI: 0 (0) SAVR: 0 (0) |
TAVI: 1 (2.9) SAVR: (0) |
|
3 months Nielsen et al, 201223 |
TAVI: 4 (11.8) SAVR: 0 (0) |
TAVI: 3 (8.8) SAVR: 0 (0) |
Severe TAVI: 2 (5.9) SAVR: 0 (0) Mild TAVI: 2 (5.9) SAVR: 0 (0) |
TAVI: 3 (8.8) SAVR: 1 (2.8) |
NA | NA | TAVI: 2 (5.9) SAVR: 1 (2.8) |
TAVI: 0 (0) SAVR: 0 (0) |
TAVI: 1 (2.9) SAVR: 0 (0) |
Abbreviations: NA, not available; SAVR, surgical aortic valve replacement; TA, transapical; TAVI, transcatheter aortic valve implantation; TF, transfemoral.